Skip to main content

Table 4 Relationships between clinicopathological variables, subcellular Hdm2 and patient outcome

From: p14ARF expression in invasive breast cancers and ductal carcinoma in situ– relationships to p53 and Hdm2

Variable Univariate analysis Multivariate analysis
  95% CI P 95% CI P
Overall survival     
   Age 0.99–1.04 0.4 0.98–2.90 0.009
   Lymph node status (+/-) 2.79–153.9 0.004 2.65–161 0.003
   Invasive tumour grade (I, II, II) 1.27–4.93 0.002 1.14–4.62 0.002
   Tumour size (cm) 1.02–1.05 <0.001 1.02–1.05 <0.001
   NPI 1.48–3.36 <0.001 1.39–3.32 <0.001
   ER quick-score 0.66–0.92 0.002 0.68–0.98 0.03
   HER-2 score 0.94–2.02 0.04 0.76–1.95 0.56
   Ki67 proliferative index 0.99–1.00 0.4 0.99–1.00 0.65
   Lymphovascular invasion (+/-) 1.46–9.38 0.006 0.89–6.69 0.08
   Hdm2 cytoplasm MQS 0.66–0.95 0.01 0.67–0.97 0.02
   Hdm2 nucleus MQS 0.68–1.01 0.07 0.69–1.05 0.13
Disease-free survival     
   Age 0.97–1.02 0.9 0.99–1.06 0.06
   Lymph node status (+/-) 2.29–25.3 <0.001 2.06–25.6 0.002
   Invasive tumour grade (I, II, II) 1.48–5.38 0.005 1.36–5.11 0.006
   Tumour size (cm) 1.02–1.04 <0.001 1.02–1.04 <0.001
   NPI 1.46–3.17 <0.001 1.38–3.15 <0.001
   ER quick-score 0.66–0.89 0.001 0.68–0.95 0.01
   HER-2 score 1.04–1.92 0.02 0.95–1.87 0.2
   Ki67 Proliferative index 0.99–1.00 0.2 0.99–1.00 0.3
   Lymphovascular invasion (+/-) 1.63–6.95 0.002 1.09–6.65 0.03
   Hdm2 cytoplasm MQS 0.73–1.02 0.05 0.70–0.98 0.03
   Hdm2 nucleus MQS 0.78–1.09 0.34 0.76–1.09 0.9
  1. Confidence intervals (CI) and P values are given for the results of both the univariate and multivariate analyses. Data for the univariate analysis were evaluable in 97 patients (reflecting the exclusion of 6 local tumour recurrences as described in the Methods section) and included a multivariate analysis on 86 cases that excluded non-evaluable Nottingham Prognostic Index (NPI) (nodes, grade and size) in 11 patients. All clinicopathological variables and subcellular Hdm2 modified Quick-scores (MQSs) were analysed as a continuum, with lymph node status and lymphovascular invasion being assessed as present or absent. Univariate and multivariate analyses for cytoplasmic Hdm2 (and nuclear Hdm2) (overall survival) were evaluated on 77 and 70 patients, respectively (85 patients univariate [disease-free survival], and 77 patients multivariate, [disease-free survival]). The multivariate analysis is adjusted for NPI and treatment (tamoxifen/chemotherapy/none). Relationships that reached significance (P < 0.05) are highlighted in bold. ER, oestrogen receptor.